To test the hypothesis that c-MET inhibition and Bcl-2/Bcl-xL inhibition acts synergistically on the reduction of cellular proliferation in model systems of glioblastoma, NCH644, GBM stem-like cells and U87 and LN229 cells were treated with a range of concentrations of the c-MET inhibitor, Crizotinib, the Bcl-2/Bcl-xL inhibitor, ABT263 or the combination of the two reagents. Here, BCL2L1 is linked to glioblastoma.